Waste Connections ( WCN ) has priced a public offering of $600 million in 4.800% senior notes due 2036 at a price of 99.732% of their face value. This offering is set to close on March 16, 2026, pending standard closing conditions. After fees and expenses, the net proceeds are expected to be about $593 million. These funds will be used, along with existing cash, to repay part of the borrowings und...
Waste Connections ( WCN ) has priced a public offering of $600 million in 4.800% senior notes due 2036 at a price of 99.732% of their face value. This offering is set to close on March 16, 2026, pending standard closing conditions. After fees and expenses, the net proceeds are expected to be about $593 million. These funds will be used, along with existing cash, to repay part of the borrowings under its revolving credit facility. More on Waste Connections Waste Connections: A Path To Double-Digit EPS Growth Despite Volume Pressures Waste Connections, Inc. (WCN) Q4 2025 Earnings Call Transcript Waste Connections plans public offering of senior unsecured notes Waste Connections targets $9.9B–$9.95B 2026 revenue as AI and acquisition gains bolster margin outlook Seeking Alpha’s Quant Rating on Waste Connections
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Google is facing a wrongful death lawsuit alleging its Gemini AI chatbot contributed to a user's self-harm. The case is described as the first of its kind against a major tech company's generative AI system. The lawsuit raises new questions about the safety ...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Google is facing a wrongful death lawsuit alleging its Gemini AI chatbot contributed to a user's self-harm. The case is described as the first of its kind against a major tech company's generative AI system. The lawsuit raises new questions about the safety controls, legal exposure, and oversight of AI chatbots. For Alphabet (NasdaqGS:GOOGL), the lawsuit comes at a time when its AI efforts sit at the center of the investment story. The stock closed at $300.88, with a 1 year return of 75.3% and a 3 year return of 228.4%, highlighting how AI expectations have been tied to the share price over time. Recent moves have been more mixed, with a 7 day return reflecting a 2.1% decline and a 30 day return reflecting an 11.4% decline. As generative AI tools like Gemini become more embedded in consumer products, investors are likely to pay closer attention to how Alphabet handles guardrails, liability, and product disclosures. The outcome of this case, together with any follow-on regulatory responses, could influence how Alphabet balances risk management for AI with its broader strategic objectives. Stay updated on the most important news stories for Alphabet by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Alphabet. NasdaqGS:GOOGL 1-Year Stock Price Chart Is Alphabet's balance sheet strong enough for future acquisitions? Dive into our detailed financial health analysis. Quick Assessment ✅ Price vs Analyst Target : At US$300.88 versus a US$376.86 analyst target, Alphabet trades about 25% below consensus. ✅ Simply Wall St Valuation : Shares are described as trading 11.6% below estimated fair value, which screens as undervalued. ❌ Recent Momentum: The 30 day return of roughly 11.4% decline shows pressure on the share price as AI headlines build. There is only one way to know t...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Palantir Technologies (NasdaqGS:PLTR) is being required by a new U.S. government directive to unwind Anthropic's Claude AI models from core military software platforms. The company is managing this operational shift while securing a Department of Homeland Se...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Palantir Technologies (NasdaqGS:PLTR) is being required by a new U.S. government directive to unwind Anthropic's Claude AI models from core military software platforms. The company is managing this operational shift while securing a Department of Homeland Security contract and a major Australian defence agreement. Senior insiders have recently sold shares as geopolitical conflict and market volatility continue to affect sentiment toward defense focused technology names. Palantir builds data analytics and AI driven software for government and commercial clients, with a long history of work in defense and security. The Pentagon move to phase out Anthropic's Claude from key U.S. military systems introduces technical and workflow risk within Palantir's core franchise. At the same time, fresh awards from the Department of Homeland Security and the Australian Defence Department highlight ongoing demand for its platforms in areas that governments treat as mission critical. For you as an investor, the combination of forced AI model changes, new contracts and insider selling creates a more complex picture rather than a single clear signal. This article explains what is changing inside Palantir's government business, how the contract wins and model unwinds might interact, and what questions you may want to ask as you consider your own risk tolerance around NasdaqGS:PLTR. Stay updated on the most important news stories for Palantir Technologies by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Palantir Technologies. NasdaqGS:PLTR 1-Year Stock Price Chart See which insiders are buying and buying and selling Palantir Technologies following this latest news. For current shareholders, the new Pentagon directive creates real execution risk. Palantir has to remove Anthropic’s Clau...
Overseas investors are pulling money out of emerging Asian stocks at the fastest pace in nearly four years as the escalating conflict in Iran triggers a reassessment of risk across global markets. Global funds have sold a net $11 billion of shares in developing Asia excluding China this week, set for the largest outflow since March 2022, according to data compiled by Bloomberg. They have withdrawn...
Overseas investors are pulling money out of emerging Asian stocks at the fastest pace in nearly four years as the escalating conflict in Iran triggers a reassessment of risk across global markets. Global funds have sold a net $11 billion of shares in developing Asia excluding China this week, set for the largest outflow since March 2022, according to data compiled by Bloomberg. They have withdrawn a record $7.9 billion from Taiwan, roughly $1.6 billion from South Korea, and about $1.3 billion from India. The outflows have contributed to a savage selloff in regional equities that included a record one-day drop in Korea’s Kospi index , and a series of trading halts in some markets. The MSCI Asia Pacific Index has slid more than 6% this week, putting it on track for its biggest loss in almost six years, and its largest underperformance versus the S&P 500 Index since April. The foreign exodus also marks a reversal of one of the most profitable trades of recent months: “Sell America, Buy Asia.” This involved rotating out of expensive US equities and into Asian ones, banking on a softer greenback, subdued inflation and demand for regional chip stocks due to the artificial-intelligence boom. Global funds had been buying Asian stocks “on expectations of a weaker dollar and benign inflation, but the flare‑up in Iran has thrown both assumptions into question,” said Gary Tan , a fund manager at Allspring Global Investments. “Investors are now reassessing whether heightened risk aversion could keep the dollar firmer for longer, and whether higher oil prices might reignite inflation pressures.” The slump in Asian equities marks a reversal from the region’s strong start to the year relative to US equities before the Iran conflict erupted, when global investors were increasingly rotating capital toward the region.
Tesla Inc. (NASDAQ:TSLA) has recorded an uptick in its reported registrations across multiple markets in the European region, in what could be a boost for the company amid falling sales. Registrations Surge 10% On Thursday, Electrek compiled registration data from 15 different territories in the region, including France, UK, Germany, Portugal and more. The company, in total, reported 17,425 regist...
Tesla Inc. (NASDAQ:TSLA) has recorded an uptick in its reported registrations across multiple markets in the European region, in what could be a boost for the company amid falling sales. Registrations Surge 10% On Thursday, Electrek compiled registration data from 15 different territories in the region, including France, UK, Germany, Portugal and more. The company, in total, reported 17,425 registrations in February, representing a 10% YoY surge from February 2025. However, Tesla's YTD registrations of 25,451 units in January and February 2026 are actually almost 2 dozen units or so shy of being identical to the 25,474 units it registered during the same time last year, the report said. The report also said that Tesla reported strong numbers in Portugal, Spain, Germany, and France, with France reporting the highest number of registrations at 3,715 units, but on the other hand, the UK (-37%), Netherlands (-45%), Denmark (-18%) and Sweden (-10%) all reported sales drops. BYD's Rise IG Metall Loses Gigafactory Berlin Benzinga Edge Rankings show that Tesla scores well on the Momentum metric and offers a favorable price trend in the Long Term. Price Action: TSLA declined 0.10% to $405.55 at market close on Thursday, but gained 0.01% to $405.60 during the after-hours session. Check out more of Benzinga’s Future Of Mobility coverage by following this link. Photo courtesy: Shutterstock
REGENXBIO NASDAQ: RGNX outlined a slate of near-term clinical catalysts and provided financial updates during its fourth-quarter and year-end 2025 earnings call, emphasizing what management described as a “pivotal year” ahead as the company advances late-stage programs in Duchenne muscular dystrophy (DMD) and retinal disease. Executives also addressed recent regulatory setbacks in its mucopolysacc...
REGENXBIO NASDAQ: RGNX outlined a slate of near-term clinical catalysts and provided financial updates during its fourth-quarter and year-end 2025 earnings call, emphasizing what management described as a “pivotal year” ahead as the company advances late-stage programs in Duchenne muscular dystrophy (DMD) and retinal disease. Executives also addressed recent regulatory setbacks in its mucopolysaccharidosis (MPS) programs, including a complete response letter (CRL) and clinical holds, and discussed ongoing interactions with the FDA as the company plans for potential biologics license application (BLA) submissions. Get REGENXBIO alerts: Sign Up RGX-202 in Duchenne: pivotal readout expected in early Q2 Chief Executive Officer Curran Simpson and Chief Medical Officer Steve Pakola highlighted RGX-202 as the company’s lead program, describing it as a potential “best-in-class” gene therapy for DMD. Management said dosing in the pivotal AFFINITY DUCHENNE trial was completed in October 2025, and that a separate confirmatory study is enrolling robustly. Top-line data from the pivotal trial are expected in the early second quarter of 2026, and the company said it plans to share additional Phase I/II data at the Muscular Dystrophy Association annual meeting the following week. REGENXBIO also reiterated its intent to pursue a BLA submission and said it plans to engage the FDA mid-year to discuss a planned submission using the accelerated approval pathway. Pakola pointed to previously disclosed functional results, including what he called a “striking” 7.4 average improvement versus a CTAP model at 18 months in the Phase I/II study. He said the data have shown consistent microdystrophin expression and that most treated patients were 8 years and older—an age when functional decline is typically expected. The company said it expects to have 12-month functional data on the majority of pivotal patients by fall 2026, and noted that the timing and content of functional data included in ...
Iran’s foreign minister said Thursday that the country is “not asking for a ceasefire” with the United States and Israel and sees no reason to enter negotiations after nearly a week of fighting. Araghchi, in an exclusive interview with NBC News, said that Iran had not made a decision to start a war with its neighbors. "We have not attacked our neighbors. We have not attacked Muslim countries," Ara...
Iran’s foreign minister said Thursday that the country is “not asking for a ceasefire” with the United States and Israel and sees no reason to enter negotiations after nearly a week of fighting. Araghchi, in an exclusive interview with NBC News, said that Iran had not made a decision to start a war with its neighbors. "We have not attacked our neighbors. We have not attacked Muslim countries," Araghchi said. "We have attacked American targets and American bases, American installations, which are unfortunately located in the soils of our neighbors." "There is no way that they can win this war . As long as it takes, we resist," he said. "So they better stop this war and stop killing our people." He said it would be “a big disaster for them” if the U.S. military invaded Iran. The comments come as President Donald Trump on Thursday said Tehran was reaching out to the United States about making a deal amid U.S. and Israeli strikes on Iran, adding that further action to reduce pressure on oil was imminent. "They're calling, they're saying 'how do we make a deal?' I said you're being a little bit late," said Trump, speaking at an event with the Inter Miami soccer team at the White House. U.S. crude oil futures ( CL1:COM ) fell 1.2% to $80.04/bbl, and Brent crude ( CO1:COM ) was down about 1% to $84.59/bbl at press time. More on markets, Archer-Daniels-Midland: Policy Wins Don't Fix This Dividend King's Valuation Politics And The Markets 03/06/26 Micron Bulls Are About To Meet Samsung's HBM4 Memory Chip (Rating Downgrade) Friday’s Economic Calendar Nutex Health reports Q4 results; authorizes stock repurchase program of up to $25M